Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ernest Wright

Neurological Surgery Nashville, TN Medical Doctor

NPI 1346569589 CMS profile 333386

2011 Murphy Ave Ste 3011, Attn: Academic Affairs, Nashville, TN 37203

Open in the dashboard

General payments

$62,902

101 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ernest Wright of Nashville, TN is reported in the CMS Open Payments database as having received $62,902 across 101 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $662 6
2024 General $444 7
2023 General $306 6
2022 General $8,308 18
2021 General $26,726 26
2020 General $19,108 16
2019 General $7,348 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ernest Wright
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Ernest Wright were reported at $662. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Ernest Wright Neurological Surgery median Middle half National median
2019 $7,348 $582 $138–$3,006 $163
2020 $19,108 $294 $76–$2,174 $114
2021 $26,726 $387 $105–$2,432 $132
2022 $8,308 $542 $139–$2,989 $149
2023 $306 $534 $145–$2,697 $160
2024 $444 $574 $155–$3,046 $164
2025 $662 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $53,807 44 payments
  2. DePuy Synthes Products, Inc. $6,267 11 payments
  3. DePuy Synthes Sales Inc. $899 15 payments
  4. Philips Electronics North America Corporation $500 4 payments
  5. Abbott Laboratories $466 12 payments
  6. Medtronic, Inc. $392 3 payments
  7. Medtronic USA, Inc. $223 7 payments
  8. Synaptive Medical Inc. $107 1 payment
  9. Cerapedics, Inc. $99 1 payment
  10. Ebi, LLC $49 1 payment
  11. Other $94 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $54,413 15 payments
  2. Travel and Lodging $5,119 19 payments
  3. Food and Beverage $3,271 66 payments
  4. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. VIPER Spine $31,670 14 payments
  2. CONDUIT Spine $31,528 14 payments
  3. Sentio $31,386 10 payments
  4. EXPEDIUM $31,278 9 payments
  5. VIPER Spine $25,036 14 payments
  6. COUGAR $23,353 9 payments
  7. CONDUIT Spine $1,641 6 payments
  8. Azurion 7 B20 $500 4 payments
  9. PROCLAIM $436 10 payments
  10. MazorX - Renaissance $182 4 payments
  11. Other $1,406 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

190

Median for Neurosurgery: 83

Drug cost

$1,788

Median for Neurosurgery: $872

Branded share of claims

31.6%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 33 $473
Gabapentin Generic 41 $373
Pregabalin Generic 15 $303
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 27 $248
Methylprednisolone Generic 21 $154
Oxycodone Hcl Generic 33 $146
Methocarbamol Generic 20 $92

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$202,394

Medicare's payments for the services billed

Medicare patients

327

Average age 73

Services billed

855

177 women, 150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 39%
Depression 32%
Diabetes 31%
Chronic kidney disease 30%
COPD 24%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

101 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record